Impact of Intravascular Fluid Resuscitation and Whole Blood Viscosity for CABG Surgery

April 28, 2016 updated by: Tae-Yop Kim, MD PhD, Konkuk University Medical Center

Impact of Intravascular Fluid Resuscitation on Whole Blood Viscosity During CABG Surgery

After obtaining approval from the Institutional Review Board of our institution, written informed consent is obtained from patients undergoing CABG surgery are enrolled in this prospective study and randomly allocated into one of two groups: Group-C (n=15) and Group-HES (n=15).

All recruited patients will be given patient identification number (PIN) for the present study of 01-30 according to their order of interview and recruitment. Investigators will prepare 15 yellow and 15 green cards, which will be inserted in 30 thick-paper envelopes. Then, all envelopes will be sealed, mixed and randomly allocated to get numbers of 01 to 30 (Envelop number).

According to the color of the card, attending anesthesiologists will give crystalloid for yellow card or HES for green cards, respectively, to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture.

Patient data and statistical analyses:

Patient's data whole blood viscosity, PaO2, FiO2, Hemoglobin, urine amount, s-glucose will be determined from the patients' medical record after patient's discharge.

All statistical analyses will be performed after the 30th patient's discharge and data acquisition

Study Overview

Status

Unknown

Conditions

Study Type

Interventional

Enrollment (Anticipated)

30

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients undergoing CABG Surgery
  • Patients provided a written informed consent.
  • Patients with preoperative serum hemoglobin concentration >13 g/dL (male) and >12 g/dL (female)
  • Patients with PaO2/FiO2 ratio >150

Exclusion Criteria:

  • Patients with history of anemia, dyspnea, active infection.
  • Patients with endocrine disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Intravenous Crystalloid
crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
Active Comparator: Intravenous HES
HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
whole blood viscosity
Time Frame: with 1 hour after the completion of procedure
whole blood viscosity measured by viscometer cm-1
with 1 hour after the completion of procedure

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PaO2/FiO2 ratio
Time Frame: with 1 hour after the completion of procedure
PaO2/FiO2 ratio measured by arterial blood gas analysis
with 1 hour after the completion of procedure
hematocrit
Time Frame: with 1 hour after the completion of procedure
serum hematocrit, %
with 1 hour after the completion of procedure
glucose
Time Frame: with 1 hour after the completion of procedure
serum glucose level, g/dl
with 1 hour after the completion of procedure
osmolarity
Time Frame: with 1 hour after the completion of procedure
serum osmolarity, mOsm
with 1 hour after the completion of procedure
urine output
Time Frame: with 1 hour after the completion of procedure
hourly urine output, ml/hr
with 1 hour after the completion of procedure
Maximum clot formation
Time Frame: with 1 hour after the completion of procedure
Maximum clot formation in rotational thromboelastometry (ROTEM) analysis, mm
with 1 hour after the completion of procedure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2016

Primary Completion (Anticipated)

October 1, 2016

Study Completion (Anticipated)

January 1, 2017

Study Registration Dates

First Submitted

April 27, 2016

First Submitted That Met QC Criteria

April 28, 2016

First Posted (Estimate)

April 29, 2016

Study Record Updates

Last Update Posted (Estimate)

April 29, 2016

Last Update Submitted That Met QC Criteria

April 28, 2016

Last Verified

April 1, 2016

More Information

Terms related to this study

Other Study ID Numbers

  • KUH000012

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on CABG Surgery

Clinical Trials on Intravenous Crystalloid

3
Subscribe